Syn-Ake: What the Research Actually Shows

Educational Notice

This article is written for researchers, formulators, clinicians, and informed consumers seeking to understand the published evidence on Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate). It is not medical advice, a treatment recommendation, or an endorsement of any product. Syn-Ake is a cosmetic ingredient — not a pharmaceutical drug — and is not evaluated by the FDA for safety or efficacy. Consult a qualified dermatologist or healthcare professional before making decisions about your skin health.

A Comprehensive Evidence Review for Researchers, Formulators, and Informed Consumers

Syn-Ake is marketed as “snake venom in a serum” — a synthetic peptide that mimics the muscle-paralyzing component of Temple Viper venom to smooth expression lines without needles. The hook works. It is one of the more evocative concepts in cosmetic ingredient marketing, and it has generated significant consumer interest and commercial adoption. The underlying science is more interesting than the marketing suggests, and also more constrained. Syn-Ake is a real peptide with a real mechanism. The evidence for that mechanism working through skin, at commercially available concentrations, is limited and almost entirely manufacturer-sponsored.

Syn-Ake is a synthetic analog of waglerin-1, a peptide toxin found in the venom of the Temple Viper (Tropidolaemus wagleri). Waglerin-1 is a potent antagonist of the muscular nicotinic acetylcholine receptor (nAChR) — the receptor that receives acetylcholine at the neuromuscular junction and triggers muscle fiber contraction. By blocking this receptor, waglerin-1 prevents acetylcholine from initiating contraction. In snake envenomation, this produces paralysis. The cosmetic hypothesis is that a synthetic analog, applied topically at much lower concentrations, could produce mild, reversible muscle relaxation at facial expression sites — a gentler version of the same endpoint.

This is a different mechanism from argireline, which targets the presynaptic SNARE complex to reduce acetylcholine release. Syn-Ake targets the postsynaptic nicotinic acetylcholine receptor to block acetylcholine signaling after it has been released. Both aim at the same functional outcome — reduced muscle contraction at the NMJ — through mechanistically distinct intervention points. Whether either reaches that target at the concentrations and penetration depths achievable through topical application is the central unanswered question for both compounds.

Quick Facts

INCI Name

Dipeptide Diaminobutyroyl Benzylamide Diacetate

Mechanism Class

Neurotransmitter inhibitor (nicotinic acetylcholine receptor antagonist)

Evidence Tier

Pilot / Limited Human Data

Regulatory Status

Cosmetic ingredient — not a drug. No FDA approval or evaluation required.

WADA Status

Not prohibited

Typical Topical Concentration

4% in published studies; 1–4% in commercial products

Molecular Weight

~582 Da — near the 500 Da passive penetration threshold

Tradename

Syn-Ake® (Pentapharm / DSM Nutritional Products)

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is Syn-Ake?

Syn-Ake (INCI: dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic tripeptide developed by Pentapharm (now part of DSM Nutritional Products) and introduced to the cosmetics market in the mid-2000s. It is a small, stabilized analog of waglerin-1 — a naturally occurring peptide toxin from the venom of the Temple Viper — designed to retain the receptor-binding activity of the original toxin at cosmetically relevant concentrations while eliminating its toxic potency.

At its target — the muscular nicotinic acetylcholine receptor at the neuromuscular junction — Syn-Ake acts as an antagonist. It competes with acetylcholine for binding at the receptor, reducing the receptor’s ability to initiate muscle fiber depolarization and contraction. The proposed cosmetic effect is mild, reversible relaxation of facial expression muscles, reducing the repetitive contractions that deepen dynamic wrinkles over time.

Syn-Ake has a lower molecular weight than argireline (approximately 582 Da versus 889 Da), placing it closer to the 500 Da passive penetration threshold — a meaningful formulation advantage. The precise sequence is a stabilized dipeptide with a benzylamide modification at the C-terminus, which improves receptor binding affinity relative to its parent waglerin-1 sequence while reducing toxicity to non-meaningful levels at cosmetic concentrations.

Origins and Development

Pentapharm developed Syn-Ake as part of a broader strategy of drawing on natural venom-derived peptide pharmacology for cosmetic applications. Snake venoms are among the richest natural sources of potent, highly selective receptor ligands — they have been refined by millions of years of predator-prey evolution to act precisely on specific neuromuscular targets. The pharmaceutical industry has leveraged venom peptides extensively (ziconotide from cone snail venom, captopril derived from pit viper venom research, eptifibatide from pygmy rattlesnake venom). Syn-Ake adapts this logic to the cosmetic context: use the receptor-targeting precision of a venom peptide, but at concentrations that produce cosmetic effect rather than toxicological effect.

The ingredient was launched commercially around 2006. DSM acquired Pentapharm and continues to market Syn-Ake globally. The clinical evidence base consists primarily of studies funded by Pentapharm/DSM, conducted at the time of the ingredient’s commercialization. Independent peer-reviewed replication is limited, consistent with the pattern seen across cosmetic peptide ingredients.

Waglerin-1: The Biological Source

Waglerin-1 is a 22-amino acid peptide toxin isolated from the venom of the Temple Viper (Tropidolaemus wagleri), a pit viper native to Southeast Asia. It is a highly selective antagonist of the ε-subunit-containing muscular nicotinic acetylcholine receptor (ε-nAChR) — the adult isoform of the receptor found at mature neuromuscular junctions. Waglerin-1 produces rapid, reversible flaccid paralysis at nanomolar concentrations in animal models. Unlike α-bungarotoxin (which binds irreversibly) or botulinum toxin (which cleaves SNARE proteins irreversibly), waglerin-1’s effect is pharmacologically reversible — the receptor recovers after the toxin is cleared.

The selectivity of waglerin-1 for the ε-nAChR isoform is relevant: this is the adult muscle receptor. The γ-subunit isoform found in fetal muscle and in some autonomic junctions is much less sensitive to waglerin-1. This selectivity reduces the theoretical risk of off-target autonomic effects, though this selectivity profile is established for the native 22-amino acid toxin and may differ for the truncated Syn-Ake analog.

Plain English

Temple Viper venom contains a molecule that temporarily paralyzes muscles by blocking the receptor that tells them to contract. Syn-Ake is a miniaturized synthetic version of that molecule, designed to be potent enough to affect muscle receptors but safe enough for cosmetic use. The concept is legitimate — venom peptides are genuinely powerful receptor tools. The question is whether a topical serum can deliver enough of it to facial muscles to do anything noticeable.

Mechanism of Action

Syn-Ake acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. When acetylcholine is released from the motor nerve terminal, it crosses the synaptic cleft and binds to nAChR on the muscle fiber membrane. This binding opens an ion channel, allowing sodium and calcium influx that depolarizes the membrane and initiates an action potential in the muscle fiber — the signal that causes contraction. Syn-Ake competes with acetylcholine for the receptor binding site. If Syn-Ake occupies the receptor instead of acetylcholine, the channel does not open, depolarization does not occur, and contraction is reduced or prevented at that junction.

This is a postsynaptic mechanism — it acts on the muscle-side receptor, after acetylcholine has already been released. Argireline, by contrast, acts presynaptically, reducing acetylcholine release before it reaches the cleft. Both ultimately target the same functional outcome (reduced contraction), but at different intervention points in the neurotransmission sequence. Whether combining both compounds produces additive effects at the NMJ is theoretically plausible but has not been studied in humans.

Plain English

Argireline reduces how much acetylcholine gets released from the nerve. Syn-Ake blocks the receptor on the muscle that acetylcholine is trying to activate. Different intervention point, same goal: less muscle contraction. Whether applying both topically simultaneously does more than either alone is an interesting question that has never been tested in a clinical trial.

The same penetration challenge applies to Syn-Ake as to argireline. The NMJ is not a superficial target — it lies at the motor end plate, at the deep surface of the superficial facial muscles. Topically applied Syn-Ake must traverse the stratum corneum, the viable epidermis, and the dermis to reach the muscle layer. Syn-Ake’s lower molecular weight (~582 Da) gives it a modest penetration advantage over argireline (889 Da), but 582 Da is still above the 500 Da passive diffusion threshold. Whether concentrations sufficient for meaningful nAChR antagonism are achievable at NMJ depth through topical application remains unmeasured in published human tissue studies.

Syn-Ake vs. Argireline: Two Routes to the Same Target

Syn-Ake Argireline
Target Postsynaptic nAChR (muscle receptor) Presynaptic SNARE complex (vesicle release machinery)
Mechanism Blocks acetylcholine receptor — prevents signaling Reduces acetylcholine release — less signal to receive
Biological source Waglerin-1 (Temple Viper venom analog) SNAP-25 N-terminal sequence (endogenous protein fragment)
Molecular weight ~582 Da — closer to 500 Da threshold 889 Da — further above 500 Da threshold
Typical studied concentration 4% 5–10%
Human clinical studies Small manufacturer-sponsored studies only Small manufacturer-sponsored studies only
Combination logic Theoretically additive — different intervention points on the same signaling pathway. Untested in humans.

Key Research Areas and Studies

In Vitro Receptor Binding Studies

Pentapharm’s development studies demonstrated Syn-Ake binding to nicotinic acetylcholine receptors in isolated receptor preparations. Competitive binding assays showed displacement of acetylcholine from the receptor site in a dose-dependent manner, confirming the proposed antagonist mechanism. Electrophysiology studies using neuromuscular junction preparations showed reduced end-plate potential amplitude in the presence of Syn-Ake at tested concentrations. These in vitro findings establish the mechanism as pharmacologically real under controlled laboratory conditions.

Human Clinical Studies

Pentapharm/DSM published clinical data for Syn-Ake from a study of 45 women (ages 40–65) who applied a 4% Syn-Ake formulation to the forehead and crow’s feet area twice daily for 28 days. Wrinkle depth was measured by silicon replica profilometry. The study reported a statistically significant reduction in wrinkle depth of approximately 52% at the forehead and 17% at the crow’s feet area versus baseline. A vehicle control comparison was included for a subset of measurements.

These are notable numbers — the 52% forehead figure in particular is higher than comparable claims for argireline. The same interpretive cautions apply: the study is manufacturer-sponsored, the sample is 45 women, independent replication does not exist in the peer-reviewed literature, and profilometry measurements are sensitive to methodology and baseline variation. The vehicle control design, while present, is not fully described in available published summaries. Whether the effect is attributable to Syn-Ake specifically or to the overall formulation cannot be confirmed from published data alone.

Evidence note: The “52% reduction in forehead wrinkles” figure that appears in Syn-Ake product marketing traces to this single manufacturer-sponsored study of 45 women at 4% concentration. It is a real measurement from a real study. It is not an independently replicated finding, and the full study methodology is not available in a peer-reviewed journal indexed in PubMed.

Penetration Studies

No published independent penetration studies for Syn-Ake have been identified in PubMed-indexed literature. Pentapharm’s technical dossier includes skin penetration data from Franz cell diffusion models showing penetration through excised skin, but these data are manufacturer-held and not independently verified. The lower molecular weight of Syn-Ake (~582 Da) relative to argireline (889 Da) gives theoretical penetration advantages. Formulation vehicle, lipophilicity, and skin preparation conditions all affect the real-world penetration profile — none of which has been independently characterized for this compound.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“Snake venom in a serum” / works like venom Technically derived from waglerin-1 venom peptide, but Syn-Ake is a synthetic analog designed for cosmetic concentrations — not actual venom and not paralytic at cosmetic use levels. The framing is accurate-ish but engineered to be evocative rather than informative. Technically grounded; intentionally sensationalized
“Reduces forehead wrinkles by 52%” Sourced from Pentapharm study, 45 women, 4% concentration, 28 days, profilometry. A real measurement. Not independently replicated. Full methodology not publicly available in peer-reviewed literature. Technically sourced; context always omitted
“Non-toxic alternative to Botox” Mechanism targets the same NMJ outcome as botulinum toxin via a different, reversible route. At cosmetic concentrations, Syn-Ake is not toxic. Whether it reaches the NMJ at effective concentrations through topical application is unconfirmed. Mechanistically plausible; efficacy vs. Botox unestablished
“SC injection delivers stronger, faster results” No published SC injection data. Same fundamental issue as argireline — SC delivery distributes compound systemically with no mechanism for selective facial NMJ targeting. Cosmetic-grade material is not manufactured to injectable sterility standards. No evidence; rationale is weak
“Works better than argireline” No head-to-head comparison study exists. Both have small manufacturer-sponsored studies reporting wrinkle reduction. Syn-Ake’s reported effect sizes are numerically larger, but the studies used different methodologies and cannot be directly compared. No comparative evidence

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

Syn-Ake’s human evidence sits in the same tier as argireline and Matrixyl 3000 — pilot / limited human data — but with important distinctions. The single published clinical study is larger than some argireline studies (45 women vs. 10–23 in some argireline studies), uses a vehicle control, and reports numerically impressive effect sizes. The full study methodology has not been published in a peer-reviewed, PubMed-indexed journal as a standalone paper — available data comes from Pentapharm/DSM technical documentation and conference presentations. This is a meaningful gap: peer review, methodology scrutiny, and independent access to raw data are not possible from manufacturer technical dossiers alone.

The ingredient has been commercially available for nearly two decades. The absence of independent clinical replication in that time — despite substantial commercial adoption — reflects the economic reality that no independent actor has sufficient incentive to fund a rigorous trial of a competitor’s proprietary ingredient. This is not evidence of inefficacy. It is evidence that the cosmetic ingredient evidence ecosystem does not generate the independent replication that characterizes pharmaceutical evidence. The honest reading: a plausible mechanism with real in vitro support, one manufacturer-sponsored clinical study suggesting meaningful effects, and no independent confirmation.

Safety, Risks, and Limitations

Topical Safety

Syn-Ake has been widely used as a cosmetic ingredient for approximately two decades without significant adverse event reports in the published literature. Topical safety at concentrations of 1–4% appears acceptable. Contact sensitization and allergic reactions have been rarely reported. The compound is not listed as a restricted or prohibited cosmetic ingredient in the EU or US. Individuals with known sensitivity to venom components or unusual receptor hypersensitivity should exercise appropriate caution, though the general topical safety profile is considered favorable.

Microneedling Safety Considerations

Microneedling with Syn-Ake solution is practiced in the self-experimentation community. The penetration rationale is similar to argireline — bypassing the stratum corneum barrier should increase dermal concentrations. For Syn-Ake, with its NMJ target deep in the muscle layer rather than in the dermis, microneedling at standard cosmetic depths (0.25–1.5 mm) would improve delivery through the epidermis and dermis, but the NMJ at the motor end plate remains deeper. Whether meaningful increases in NMJ-level Syn-Ake concentration are achievable with cosmetic microneedling has not been studied.

The standard sterility concerns apply. Cosmetic-grade Syn-Ake is not manufactured to pharmaceutical sterility standards. Introducing non-sterile cosmetic solutions below the stratum corneum carries infection risk that must be weighed against the uncertain benefit of increased penetration to a target whose accessibility through this route remains uncharacterized.

Subcutaneous Injection Safety

Subcutaneous injection of Syn-Ake has no published safety or pharmacokinetic data in humans or animals. The pharmacological argument against SC injection is the same as for argireline: SC delivery creates a systemic depot with no mechanism for selective concentration at facial NMJs. A systemically distributed nAChR antagonist would have access to nicotinic receptors throughout the body — not just in facial muscles. The ε-nAChR selectivity of the parent waglerin-1 peptide provides some theoretical safety buffer relative to broader nAChR antagonists, but this selectivity profile has not been confirmed for Syn-Ake following SC administration in humans.

Safety Note

SC injection of a nicotinic acetylcholine receptor antagonist — even a mild, selective one — without published pharmacokinetic data, without injectable-grade sterility, and without clinical safety assessment represents an unusual risk profile. The compound is derived from a venom toxin that produces paralysis at higher concentrations. The cosmetic concentration is designed to be safe topically. The safety profile at systemically distributed concentrations from SC injection is genuinely unknown. This is one case where “no data” is especially important to take seriously.

Legal and Regulatory Status

Syn-Ake is regulated as a cosmetic ingredient in the United States and European Union. No FDA pre-market approval is required for cosmetic use. In the EU, it falls under Regulation EC 1223/2009 — a Cosmetic Product Safety Report is required, and the ingredient must be assessed as safe for use, but clinical efficacy trials are not mandated. The ingredient appears on ingredient labels as “dipeptide diaminobutyroyl benzylamide diacetate” and is permitted in cosmetic formulations without specific concentration restrictions in either jurisdiction.

Marketing claim framing follows the same cosmetic/drug distinction applicable to all NMJ-targeting cosmetic peptides. Claims about “relaxing facial muscles” or “blocking nerve signals” are drug-class claims in the US; “reduces the appearance of expression lines” is a cosmetic claim. Manufacturers stay within cosmetic claim language in regulated markets.

WADA status: not prohibited. No restrictions for athletes subject to anti-doping testing.

Research Protocols and Formulation Considerations

Concentration: The clinical study used 4% Syn-Ake. Pentapharm recommends 2–4% in formulations. Commercial products range from 1–4%. As with all cosmetic peptides, concentration relative to the studied range is a critical variable that product marketing almost never discloses. A 1% Syn-Ake product is not equivalent to a 4% one.

Stability: Syn-Ake is reported to be stable across a broad pH range (4–9) and compatible with most cosmetic actives. It is heat-stable up to approximately 40°C (104°F), making it compatible with standard emulsion manufacturing processes. Compatibility with strong oxidizers should be assessed formulation-specifically.

Combination formulations: Syn-Ake is frequently combined with argireline in multi-peptide formulations on the basis that the two compounds target the same NMJ outcome through mechanistically complementary presynaptic and postsynaptic pathways. This is pharmacologically coherent as a hypothesis. Whether the combination produces additive or synergistic wrinkle reduction in humans has not been studied. The combination is mechanistically rational but evidentially unproven.

Application site: The clinical study focused on the forehead and crow’s feet — areas where dynamic expression wrinkles are most prominent and where facial muscle activity is concentrated. Application to these target areas is more appropriate than general facial application if the NMJ-targeting mechanism is the primary rationale.

Dosing and Delivery: What the Research Shows

Topical Application

The Pentapharm clinical study applied 4% Syn-Ake twice daily for 28 days to the forehead and periorbital areas. This is the only concentration with human outcome data. Pentapharm recommends 2–4% for cosmetic formulations. The study duration of 28 days is shorter than the 60-day protocol in Robinson 2005 for Matrixyl 3000, which is appropriate for a compound targeting a rapidly reversible mechanism — wrinkle depth changes attributable to muscle relaxation (as opposed to collagen synthesis) should be observable within weeks rather than months if the mechanism is active.

Because Syn-Ake’s effect is mechanistically reversible — receptor antagonism ceases when the compound is cleared — effects would be expected to diminish after discontinuation. Ongoing application is required to maintain any benefit, analogous to argireline and in contrast to collagen-stimulating compounds like Matrixyl 3000, which may produce more durable structural effects.

Microneedling / Stamping

Microneedling with Syn-Ake solution is used in the self-experimentation community. No Syn-Ake-specific microneedling clinical data exists. The lower molecular weight of Syn-Ake (~582 Da) gives it a theoretical penetration advantage over argireline when either is used topically or with microneedling assistance. Community practice involves dissolving Syn-Ake in bacteriostatic water or sterile saline at concentrations of 1–4% and applying during or after microneedling at 0.5–1.0 mm depth. The same sterility limitations apply as for all cosmetic-grade microneedling applications.

Subcutaneous Injection

No published pharmacokinetic, safety, or efficacy data exists for SC injection of Syn-Ake. The pharmacological argument against SC injection is the same as for argireline: systemic distribution provides no mechanism for selective facial NMJ targeting. A systemically distributed nAChR antagonist distributes to nicotinic receptors throughout the body. For Syn-Ake specifically — a compound with venom-derived receptor-blocking activity — the absence of human safety data at systemic exposure levels is an especially significant concern. Cosmetic-grade Syn-Ake is not manufactured to injectable sterility standards. SC injection of Syn-Ake has no defensible evidence basis.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Risks
Topical serum/cream Very common — standard cosmetic use Pentapharm study, 45 women, 4%, 28 days; in vitro receptor binding data Low — good topical safety record; commercial products often below studied 4% concentration
Microneedling / stamping Practiced in peptide community; less common than argireline microneedling No Syn-Ake-specific trials; general microneedling penetration rationale; lower MW than argireline is a theoretical advantage Moderate — sterility of cosmetic-grade source material; NMJ depth still below typical microneedling range
SC injection Rare in community; encountered in some biohacking forums No published data of any kind Higher — venom-derived nAChR antagonist with no systemic safety data; non-sterile source material; no facial NMJ targeting rationale for systemic delivery

Community-reported topical use follows standard serum protocol at 1–4% concentration, applied once or twice daily to expression-line areas. Syn-Ake is frequently combined with argireline in DIY serum formulations on the complementary presynaptic/postsynaptic rationale. Microneedling use involves dissolving Syn-Ake in bacteriostatic water at similar concentrations to argireline microneedling protocols. SC injection is rare and without coherent pharmacological justification — community members who have tried it report inconsistent results, which is consistent with the expectation that systemic distribution would not produce facial-specific effects.

Frequently Asked Questions

Q: Does Syn-Ake actually work?

A: The mechanism is pharmacologically real in vitro — Syn-Ake demonstrably binds to and antagonizes the muscular nAChR at the concentrations tested in laboratory preparations. The clinical evidence consists of one manufacturer-sponsored study (45 women, 4% concentration, 28 days) reporting 52% forehead and 17% crow's feet wrinkle depth reduction. This study has not been independently replicated in a peer-reviewed journal. The evidence is better than no evidence, but the context that product marketing consistently omits is that it is small-scale, manufacturer-sponsored, and not independently verified.

Q: What concentration of Syn-Ake is effective?

A: The clinical study used 4%. Pentapharm recommends 2–4% for cosmetic formulations. Many commercial products contain 1–2%, below the studied concentration. As with all cosmetic peptides, a lower-concentration product cannot be assumed to produce the same effects measured at higher concentrations in clinical studies. Concentration is one of the most important variables in evaluating cosmetic peptide formulations.

Q: Can Syn-Ake be used with microneedling?

A: It can be, and the lower molecular weight of Syn-Ake (~582 Da) compared to argireline (889 Da) gives it a modest theoretical penetration advantage. No Syn-Ake-specific microneedling clinical trial exists. The same critical safety consideration applies as for all microneedling with cosmetic-grade peptides: source material sterility. Cosmetic-grade Syn-Ake is not manufactured to pharmaceutical sterility standards, and introducing any non-sterile solution below the stratum corneum carries infection risk.

Q: Is SC injection of Syn-Ake safe?

A: There is no published safety data for SC injection of Syn-Ake. SC delivery creates a systemic depot with no mechanism for selective concentration at facial neuromuscular junctions — a systemically distributed nAChR antagonist distributes to nicotinic receptors throughout the body, not specifically to facial muscles. For a compound derived from a venom toxin with receptor-blocking activity, the absence of systemic safety data at SC doses is a particularly significant concern. Cosmetic-grade Syn-Ake is not manufactured to injectable standards. SC injection of Syn-Ake lacks both evidence and sound pharmacological rationale.

Q: How long does Syn-Ake take to work?

A: The clinical study measured outcomes at 28 days with twice-daily application. Because Syn-Ake's mechanism is reversible receptor antagonism — not structural collagen changes — effects should theoretically appear and diminish more rapidly than collagen-stimulating peptides. Any benefit requires ongoing application to maintain. If Syn-Ake topically produces any meaningful effect, it likely becomes apparent within 4–8 weeks of consistent use at appropriate concentrations.

Q: Can Syn-Ake be safely combined with Argireline?

A: Yes. Combining Syn-Ake (postsynaptic nAChR antagonist) with Argireline (presynaptic SNARE inhibitor) is mechanistically rational — the two compounds target different intervention points in the same neuromuscular transmission pathway. A combination could theoretically produce additive NMJ inhibition. Whether this combination actually produces greater wrinkle reduction in humans than either compound alone has not been tested in a published clinical trial. The combination is mechanistically plausible but evidentially unproven.

Syn-Ake shares the neurotransmitter inhibitor niche in the cosmetic peptide landscape with argireline and Leuphasyl, but operates through a distinct postsynaptic mechanism. Its venom-derived origin and nAChR antagonism set it mechanistically apart from SNARE-targeting peptides. It is frequently marketed and formulated alongside argireline precisely because the two target different points in the same neuromuscular transmission pathway. The table below shows all twelve compounds in the Skin & Cosmetic cluster with their mechanisms, evidence tiers, and delivery route data for direct comparison.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Skin Target / Mechanism Typical Concentration Route Key Differentiator
Argireline (Acetyl Hexapeptide-3) Synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, SNAP-25 modulator) SNARE complex disruption / Botox-like wrinkle reduction (proposed) ~2–4 hours (topical; serum stability uncertain) Not FDA-approved (cosmetic ingredient, GRAS status for topical use) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (periorbital, forehead); muscle contraction inhibition (proposed topical analog to botulinum toxin mechanism) Typically 3–5% in cosmetic formulations Topical (creams, serums, cosmetics) Botox alternative for topical use. Synthetic SNARE inhibitor design. Limited published clinical efficacy vs. marketing claims
Matrixyl (Palmitoyl Pentapeptide-4) Synthetic pentapeptide conjugated to palmitic acid (Pal-GVQPR, collagen-stimulating) Procollagen upregulation (TGF-β pathway proposed); collagen I/III synthesis ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; fine-line reduction; skin firmness (proposed) Typically 1–3% in cosmetic formulations Topical (creams, anti-aging serums) First-generation palmitoyl peptide anti-aging cosmetic. Synthetic TGF-β mimic. Limited independent clinical validation
Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Blend) Synthetic blend of two palmitoyl peptides (Pal-GHK + Pal-GHKGQ, synergistic collagen/elastin remodeling) Dual collagen + elastin upregulation (proposed; broader TGF-β pathway activation) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient blend) Not WADA-listed (topical cosmetic peptide blend) Tier 4 — Preclinical Only Dermal collagen and elastin remodeling; wrinkle depth and skin texture improvement (proposed) Typically 1–3% in cosmetic formulations (as synergistic blend) Topical (creams, serums, moisturizers) Second-generation peptide blend (Matrixyl + Palmitoyl Tetrapeptide-7). Synergistic formulation strategy. Limited peer-review studies
Snap-8 (Acetyl Octapeptide-3) Synthetic octapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Gly-Gly-NH2, extended Argireline analog) Extended SNARE modulation / Acetylcholine inhibition (proposed Botox alternative) ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (dynamic lines); neuromuscular junction relaxation analog (topical) Typically 2–5% in cosmetic formulations Topical (creams, serums, eye patches) Extended Argireline with two additional amino acids. Claimed improved potency vs. Argireline. Minimal peer-reviewed efficacy data
Leuphasyl (Hexapeptide-11) Synthetic hexapeptide (Palmitoyl-Pro-Asn-Thr-Asn-Leu-Ala, matrix metalloproteinase inhibitor proposed) MMP inhibition (skin-matrix degradation prevention); collagen preservation ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Matrix preservation (anti-MMP); collagen/elastin fiber integrity; skin sagging prevention (proposed) Typically 2–4% in cosmetic formulations Topical (serums, firming creams) MMP-inhibitor design rationale. Alternative to collagen-upregulating peptides. Limited cosmetic industry data
Palmitoyl Tripeptide-1 (Pal-GHK) Synthetic tripeptide conjugated to palmitic acid (Pal-Gly-His-Lys, copper-chelating glycine-histidine-lysine) Copper chelation (collagen synthesis via Lox upregulation); wound healing reactivation ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen cross-linking; elastin remodeling; scar remodeling (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, creams) Core component of Matrixyl and Matrixyl 3000. Copper-dependent mechanism. Palmitoyl modification enhances skin penetration
Palmitoyl Tetrapeptide-7 (Pal-GHKGQ) Synthetic tetrapeptide conjugated to palmitic acid (Pal-Gly-His-Lys-Gly-Gln, extended GHK variant with elastin-targeting residues) Elastin upregulation; integrin signaling activation (proposed); elastin-specific pathway ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Elastin remodeling (distinct from collagen pathway); skin elasticity and bounce; fine-line reduction (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, firming creams) Extended GHK variant targeting elastin specifically. Synergistic with Palmitoyl Tripeptide-1 in Matrixyl 3000
Syn-Ake (Dipeptide Diethylaminobutyroyl Benzylamide Diacetate, Snake Venom Mimetic Peptide) Synthetic dipeptide-conjugate mimicking snake venom neurotoxins (synthetic neuro-blocking peptide) Neuromuscular junction analog blockade (topical snake venom mimic); acetylcholine inhibition ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression line relaxation (periorbital wrinkles); dynamic wrinkle reduction (snake venom analog mechanism topical) Typically 1–3% in cosmetic formulations Topical (eye creams, serums, patches) Snake venom analog mechanism. Branded as natural-origin alternative to botulinum toxin. Limited clinical efficacy studies
Acetyl Tetrapeptide-5 (SNAP-25 Mimic) Synthetic tetrapeptide (Ac-Glu-Glu-Met-Gln, acetylated SNARE domain fragment) SNAP-25 modulation (neuromuscular junction-like topical effect, proposed) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression lines (wrinkle reduction, proposed Botox analog); muscle-relaxation topical effect Typically 2–5% in cosmetic formulations Topical (anti-wrinkle serums, creams) Short SNAP-25 fragment. Purported Botox alternative via topical neuromuscular effects. Minimal published efficacy data
Palmitoyl Hexapeptide-12 Synthetic hexapeptide conjugated to palmitic acid (Pal-containing; proprietary exact sequence variable by supplier) Broad dermal remodeling (collagen + elastin + proteoglycan synthesis proposed) ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient, proprietary formulations) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Multi-target dermal remodeling (collagen, elastin, GAGs); hydration and firmness (proposed) Typically 1–3% in cosmetic formulations Topical (moisturizers, anti-aging serums) Extended hexapeptide with broader claimed targets than Tripeptide-1 or Tetrapeptide-7. Proprietary variations limit standardization
AHK-Cu (Copper Tripeptide: Ala-His-Lys + Cu²⁺) Synthetic tripeptide-copper complex (alanine-histidine-lysine chelated to Cu²⁺, GHK-Cu analog) Collagen synthesis (copper-dependent lysyl oxidase activation); similar mechanism to GHK-Cu topical ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; anti-aging (collagen-dependent wrinkle reduction); scar appearance improvement Typically 0.5–2% in cosmetic formulations Topical (serums, creams; AHK-Cu generally topical only, unlike GHK-Cu) GHK-Cu alternative with alanine substitution. More stable copper complex than GHK-Cu in some formulations. Cosmetic-grade copper peptide
Tripeptide-29 (Proprietary Sequence, Collagen-Targeting Peptide) Synthetic tripeptide (exact sequence proprietary; collagen I/III targeting proposed) Collagen-specific upregulation (proprietary mechanism); dermal matrix support ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Collagen I and III upregulation; skin resilience and firmness (proposed); anti-sagging Typically 1–2% in cosmetic formulations Topical (anti-aging creams, serums) Proprietary peptide composition (exact sequence not published). Limited third-party efficacy studies

Summary and Key Takeaways

Syn-Ake is a genuinely interesting cosmetic ingredient with a real biological source, a real receptor-binding mechanism, and manufacturer-sponsored clinical data showing measurable wrinkle reduction at 4% topical concentration. The “snake venom” marketing is sensationalized but not fabricated — the pharmacological lineage from waglerin-1 to Syn-Ake is legitimate. The evidence gaps are the same as for the other NMJ-targeting cosmetic peptides: small manufacturer-sponsored studies, no independent replication, unconfirmed penetration to NMJ depth, and a commercial safety profile established only for topical use. SC injection of a venom-derived nAChR antagonist with no systemic safety data is a risk that has no defensible evidence basis.

  • Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic analog of waglerin-1, a Temple Viper venom peptide. It is not actual venom — it is a stabilized synthetic mimic designed for cosmetic concentrations.
  • Mechanism: postsynaptic nicotinic acetylcholine receptor (nAChR) antagonist. Blocks acetylcholine signaling at the muscle fiber after release, reducing contraction. Mechanistically distinct from and complementary to argireline’s presynaptic SNARE inhibition.
  • Molecular weight (~582 Da) is lower than argireline (889 Da), giving a modest topical penetration advantage — though both remain above the 500 Da passive diffusion threshold.
  • One manufacturer-sponsored clinical study (45 women, 4%, 28 days) reports 52% forehead and 17% crow’s feet wrinkle depth reduction. Not independently replicated. Full methodology not published in a peer-reviewed, PubMed-indexed journal.
  • Topical use at 2–4% is the evidence-supported route. Microneedling has theoretical penetration rationale. SC injection has no data and specifically concerning implications for a venom-derived nAChR antagonist distributed systemically.
  • Effects are mechanistically reversible — requires ongoing application to maintain any benefit.
  • Frequently combined with argireline in multi-peptide formulations targeting the same NMJ outcome from complementary angles. The combination is mechanistically rational but clinically unstudied.
  • WADA: not prohibited. Regulatory: cosmetic ingredient, not a drug. No FDA evaluation required or conducted.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. McArthur JR, et al. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Biol Chem. 1999;274(14):9466–72. PMID 10092629 — foundational waglerin-1 receptor pharmacology
  2. Molles BE, et al. Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors. J Biol Chem. 2002;277(8):5849–57. PMID 11741948
  3. Pentapharm/DSM technical dossier: Syn-Ake®. Clinical efficacy and safety data on file, DSM Nutritional Products. Available at: dsm.com
  4. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–45. PMID 19624730
  5. Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016
  6. Utkin YN. Animal venom studies: current benefits and future developments. World J Biol Chem. 2015;6(2):28–33. PMID 26009700 — context for venom-derived peptide pharmacology

Further Reading and References

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any cosmetic product, formulation, or delivery method.

Syn-Ake is a cosmetic ingredient, not an FDA-approved drug. It has not been evaluated by the FDA for safety or efficacy. The fact that Syn-Ake is derived from a venom peptide does not alter its cosmetic regulatory classification. Cosmetic ingredients are not subject to the same pre-market safety and efficacy evaluation required of pharmaceutical drugs.

All citations link to primary sources where available. Manufacturer-sponsored studies are identified as such. Readers are encouraged to evaluate the evidence independently and consult a qualified dermatologist or healthcare professional before making decisions about skin care.

Scroll to Top